Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 25 , ISSUE 10 ( October, 2021 ) > List of Articles

CASE SERIES

Mucormycosis: A Case Series of Patients admitted in Non-COVID-19 Intensive Care Unit of a Tertiary Care Center during the Second Wave

Sangam Yadav, Ankur Sharma, Nikhil Kothari, Pradeep K Bhatia, Shilpa Goyal, Amit Goyal

Keywords : COVID-19, Intensive care unit, Mucormycosis

Citation Information : Yadav S, Sharma A, Kothari N, Bhatia PK, Goyal S, Goyal A. Mucormycosis: A Case Series of Patients admitted in Non-COVID-19 Intensive Care Unit of a Tertiary Care Center during the Second Wave. Indian J Crit Care Med 2021; 25 (10):1191-1194.

DOI: 10.5005/jp-journals-10071-23986

License: CC BY-NC 4.0

Published Online: 30-09-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Rhino-orbital-cerebral mucormycosis is an invasive fungal infection associated with mortality of 25 to 62%. There has been a surge in the number of cases during this second wave of coronavirus disease 2019 (COVID-19) in India. We report 10 cases of mucormycosis admitted to our adult intensive care unit. After reviewing the patient\'s information, we found that 60% of patients had received steroids, and most had uncontrolled blood sugar levels. Most patients received treatment with surgical debridement and antifungal, although the mortality rate was as high as 40%. We report two unique cases of renal and gastrointestinal mucormycosis as well. We concluded that poor glycemic control was the primary etiology behind the rise in the number of cases. Our report also stresses the importance of early surgical intervention and suggests further research comparing the efficacy of combination antifungal therapy versus single antifungal (amphotericin B) to help resource-limited settings in these times of drug crisis.


PDF Share
  1. Kauffman CA, Malani AN. Zygomycosis: an emerging fungal infection with new options for management. Curr Infect Dis Rep 2007;9(6):435–440. DOI: 10.1007/s11908-007-0066-4.
  2. Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi 2019;5(1):26. DOI: 10.3390/jof5010026.
  3. Mishra N, Mutya VSS, Thomas A, Rai G, Reddy B, Mohanan AA, et al. A case series of invasive mucormycosis in patients with COVID19 infection. Int J Otorhinolaryngol Head Neck Surg 2021;7(5):867–870. DOI: 10.18203/issn.2454-5929.ijohns20211583.
  4. Mathew G, Arumugam V, Murugesan S, Duhli N, Agarwal I. Renal mucormycosis: a rare cause of urinary tract infection leading to end-stage renal disease (ESRD). J Trop Pediatr 2019;65(4):405–408. DOI: 10.1093/tropej/fmy059.
  5. Monte Junior ESD, Santos MELD, Ribeiro IB, Luz GO, Baba ER, Hirsch BS, et al. Rare and fatal gastrointestinal mucormycosis (zygomycosis) in a COVID-19 patient: a case report. Clin Endosc 2020;53(6):746–749. DOI: 10.5946/ce.2020.180.
  6. Balai E, Mummadi S, Jolly K, Darr A, Aldeerawi H. Rhinocerebral mucormycosis: a ten-year single centre case series. Cureus 2020;12(11):e11776. DOI: 10.7759/cureus.11776.
  7. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med 1999;159(12):1301–1309. DOI: 10.1001/archinte.159.12.1301.
  8. Riley TT, Muzny CA, Swiatlo E, Legendre DP. Breaking the mold: a review of mucormycosis and current pharmacological treatment options. Ann Pharmacother 2016;50(9):747–757. DOI: 10.1177/1060028016655425.
  9. Sathe KP, Mehta KP. Irreversible fatal renal failure resulting from isolated renal mucormycosis. Saudi J Kidney Dis Transpl 2014;25(6):1312–1314. DOI: 10.4103/1319-2442.144298.
  10. Rodríguez MM, Serena C, Mariné M, Pastor FJ, Guarro J. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother 2008;52(10):3786–3788. DOI: 10.1128/AAC.00628-08.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.